Fluoroquinolone resistance profile of Klebsiella pneumoniae isolates and the mechanisms conferring antibiotic resistance in ST494 strains
10.16718/j.1009-7708.2018.03.008
- VernacularTitle:肺炎克雷伯菌临床株喹诺酮类耐药性及ST494型菌株耐药机制分析
- Author:
Jinyi YUAN
1
;
Xiaogang XU
;
Fupin HU
;
Yan GUO
;
Yang YANG
;
Dong DONG
;
Qingqing XU
;
Baixing DING
;
Minggui WANG
Author Information
1. 复旦大学附属华山医院抗生素研究所
- Keywords:
Klebsiella pneumoniae;
quinolones;
drug resistant;
multilocus sequence typing
- From:
Chinese Journal of Infection and Chemotherapy
2018;18(3):286-291
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the resistance profile of Klebsiella pneumoniae isolates in Huashan Hospital, Fudan University. Methods The MICs of fluoroquinolones were determined by agar dilution method against 112 clinical strains of K. pneumoniae. Multilocus sequence typing (MLST) were applied to 48 K. pneumoniae strains. The characteristic sequence type (ST) associated with antibiotic resistance was identified by PCR. Results Lower percentage (＜40％) of K. pneumoniae strains were susceptible to fluoroquinolones. Majority (86.2％) of ciprofloxacin non-susceptible K. pneumoniae strains belonged to CC1 (ST11), ST494 or CC4 (ST15 and ST655), indicating the potential of clonal dissemination. ST494 (18.8％) was the second commonest sequence type, next only to ST11. ST494 strains harbored the genes encoding beta-lactamases, oqxAB, qnrD, aac-(6')-lb-cr and armA and had a single point mutation in gyrA. Therefore, ST494 strains were highly resistant to cephalosporins, fluoroquinolones and aminoglycosides and 22％ of the strains were resistant to carbapenems. However, all the ST494 strains were susceptible to tigecycline and tetracycline. Conclusions ST11 and ST494 are the commonest STs of K. pneumoniae conferring multidrug resistance in this hospital. These STs may contribute to the high resistance rates of K. pneumoniae to fluoroquinolones. The susceptibility of ST494 strains to tigecycline and tetracycline allows us to consider the promising potential of such drugs in managing K. pneumoniae infections.
